Coherus BioSciences, Inc. (CHRS)
| Market Cap | 222.73M |
| Revenue (ttm) | 257.24M |
| Net Income (ttm) | -237.89M |
| Shares Out | 111.36M |
| EPS (ttm) | -2.53 |
| PE Ratio | n/a |
| Forward PE | 6.80 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,890,060 |
| Open | 2.150 |
| Previous Close | 2.150 |
| Day's Range | 1.990 - 2.185 |
| 52-Week Range | 1.430 - 8.330 |
| Beta | 0.51 |
| Analysts | Strong Buy |
| Price Target | 8.75 (+337.5%) |
| Earnings Date | May 6, 2024 |
About CHRS
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal ant... [Read more]
Financial Performance
In 2023, CHRS's revenue was $257.24 million, an increase of 21.89% compared to the previous year's $211.04 million. Losses were -$237.89 million, -18.46% less than in 2022.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for CHRS stock is "Strong Buy." The 12-month stock price forecast is $8.75, which is an increase of 337.50% from the latest price.
News
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion – – ...
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
– Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA® net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 – – CIMERLI® net sales ...
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
REDWOOD CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2023 financial results will be releas...
Coherus Completes Divestiture of Ophthalmology Franchise
– Upfront cash payment of $170 million strengthens capital structure – – Transaction solidifies Coherus' strategic focus in oncology – REDWOOD CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Coherus ...
Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective February 20, 2024, the compensation committ...
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
– Innovative design enables five-minute pegfilgrastim-cbqv delivery time – – Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receiving UDE...
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
- Estimated balance of $75 million upon $175 million paydown of principal projected in Q2 2024 - - Revenue covenant reduced to $125 million - - Term loan annual interest expense projected to be reduce...
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
– Transaction aligns to Coherus' strategic focus on oncology –– Conference call Monday, January 22, 2024, at 8:30 a.m. Eastern Time –
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
– Data demonstrate early activity with casdozokitug/atezolizumab/bevacizumab; 38% objective response rate including three complete responses –
INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)
- Combination therapy to be evaluated in a Phase 3 trial in patients with locoregionally advanced , high-risk , HPV16/18 - positive head and neck cancer PLYMOUTH MEETING, Pa. and REDWOOD CITY, Cal...
Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” Nasdaq: CHRS), today announced that senior management will present at the upcoming 42nd Annual J.P. Morgan...
Coherus Announces U.S. Launch of LOQTORZI™
– Launch of LOQTORZI offers first and only FDA-approved treatment for NPC in all lines of therapy – – Indicated in combination with chemotherapy for 1 st line treatment and as monotherapy for patient...
2024 could turn into a ‘trader's market.' Here's how this strategist says you can make the most of that.
The S&P 500 index SPX has three days left this year to try for a fresh record high, which in theory, shouldn't be so hard with a Santa Rally all but teed up.
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
– Innovative design enables five-minute pegfilgrastim delivery time – – Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receiving pegfilgr...
Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx
– NCCN Guidelines recommend LOQTORZI as the only Preferred Category 1 treatment option in first-line treatment for adults with metastatic or recurrent locally advanced NPC in combination with chemothe...
Coherus BioSciences Announces CFO Transition Plans
REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that McDavid Stilwell, Chief Financial Officer (CFO), has resigned from the c...
Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress
– Casdozokitug has demonstrated anti-tumor activity alone and in combination with an anti-PD-1 antibody; two of nine squamous NSCLC patients had confirmed partial responses –
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
– Net revenue rose 27% from prior quarter to $74.6 million – – CIMERLI® net sales increased 50% to $40 million compared to prior quarter – – LOQTORZI™ now approved with launch planned for the first qu...
Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)
– Data demonstrate distinct IL-27-mediated expression of genes associated with immune suppression in vitro, supporting ongoing clinical development of first-in-class anti-IL-27 antibody casdozokitug –
Coherus BioSciences to Participate at Upcoming November Investor Conferences
REDWOOD CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conference...
Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023
REDWOOD CITY, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that its third quarter 2023 financial results will be released after market ...
Intuitive Machines stock climbs on lunar mission plan as McDonald's edges higher ahead of results
Coherus BioSciences stock CHRS, -3.65% rose 17% as the Food and Drug Administration approved its treatment for nasopharyngeal cancer when combined with chemotherapy that it makes with Shanghai Junshi ...
Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
— Data demonstrate preclinical potent T cell activation and differentiated mechanism of action and enhanced clinical efficacy irrespective of PD-L1 status when administered in combination with chemoth...
Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™
– Resubmission follows the satisfactory resolution of the FDA's review of inspection findings at the third-party filler –
CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch
– CIMERLI® is the #1 ranibizumab biosimilar with 25% ranibizumab market share* – – Demonstrated safety and efficacy in clinical trials and real-world settings – – Robust and reliable supply addresses ...